COLY-MYCIN M 150 MG
COLISTIN (COLISTIMETHATE SODIUM) : 150 MG · DIN 00476420 · SEARCHLIGHT PHARMA INC
Health Canada status: MARKETED
What is COLY-MYCIN M?
COLY-MYCIN M 150 MG contains COLISTIN (COLISTIMETHATE SODIUM) : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 00476420, held by SEARCHLIGHT PHARMA INC, supplied as POWDER FOR SOLUTION for INTRAMUSCULAR ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 25-Jul-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is COLY-MYCIN M used for?
COLY-MYCIN M (colistimethate sodium for injection U.S.P.) is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. Particularly indicated when the infection is caused by sensitive strains of P. aeruginosa. This antibiotic is not indicated for infections due to proteus or neisseria. Sodium colistimethate has proven clinically effective in treatment of infections due to the following gram-negative organisms: A. aerogenes, E. coli, K. pneumoniae and P. aeruginosa. Pending results of appropriate bacteriologic cultures and sensitivity tests, sodium colistimethate may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of COLY-MYCIN M and other antibacterial drugs, COLY-MYCIN M should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00476420 |
|---|---|
| Brand name | COLY-MYCIN M |
| Generic / active ingredient | COLISTIN (COLISTIMETHATE SODIUM) : 150 MG |
| Manufacturer | SEARCHLIGHT PHARMA INC |
| Strength | 150 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAMUSCULAR ; INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01XB01 COLISTIN |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 25-Jul-2024 |
How is it stored and handled?
Store COLY-MYCIN M at controlled room temperature between 15°C and 30°C. After reconstitution, COLY-MYCIN M solution should be stored refrigerated 2°C to 8°C and used within 3 days (or within 24 hours, when stored at controlled room temperature 15°C to 30°C). Any infusion solution containing colistimethate sodium should be freshly prepared and used for no longer than 24 hours.
How is it supplied?
Vial size 10 mL
What can be used instead?
Other Canadian products sharing ATC code J01XB01 COLISTIN. 4 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| COLISTIMETHATE FOR INJECTION U.S.P. | 150 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02244849 |
| COLISTIMETHATE FOR INJECTION USP | 150 MG | POWDER FOR SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02546639 |
| COLISTIMETHATE FOR INJECTION, USP | 150 MG | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02403544 |
Who else supplies COLISTIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. COLISTIN appears in 20 registered pack listings across 3 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.